Agios Presents Updated Data on PYRUKYND® (Mitapivat)
– Actively initiating the Phase 3 ENERGIZE and ENERGIZE-T studies evaluating PYRUKYND® in adults with non-transfusion-dependent or transfusion-dependent α- or β-thalassemia – – Agios to
Home » PYRUKYND
– Actively initiating the Phase 3 ENERGIZE and ENERGIZE-T studies evaluating PYRUKYND® in adults with non-transfusion-dependent or transfusion-dependent α- or β-thalassemia – – Agios to
When inventors need an NDA, what it actually protects, and the routine confidentiality habits that keep patent options open before filing.
Recovery after a serious car accident often takes weeks to months, while severe injuries may require a year or longer. The first 72 hours usually
As remote work becomes a permanent fixture of American employment, a new national study from John Foy & Associates uncovers the rising dangers hiding behind